Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06117384

Systems Oncology Approach to Optimize Ovarian Cancer Treatment

The overall aim is to identify effective therapeutic strategies to ovarian cancer (OC) using serial tumor, ascites and blood samples, and carry out state-of-the-art sequencing approaches, functional assays and associated bioinformatics to understand mechanisms behind chemoresistance in OC and identify new treatment options for OC patients. In this observational trial, we will systematically collect, analyze and interpret functional, molecular and clinical data from real-world ovarian cancer patients.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Ovarian Cancer Adnexal Diseases Endocrine Gland Neoplasms Endocrine System Diseases Female Urogenital Diseases Female Urogenital Diseases and Pregnancy Complications Genital Diseases Genital Diseases, Female Genital Neoplasms, Female Gonadal Disorders Neoplasms Neoplasms by Site Ovarian Diseases Ovarian Neoplasms Urogenital Diseases Urogenital Neoplasms

Sex eligibility

Female

Study type

Observational

Primary location

Helsinki University and Helsinki University Hospital

Helsinki, 00014, Finland

Location status: Recruiting

Location contact

Anniina Färkkilä, MD PhD

CONTACT

[email protected]

+358504272060

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients diagnosed with ovarian cancer
  • Available tumor tissue/blood samples

Exclusion criteria

  • Inability to consent to the study

Treatment and study plan

Biomolecular profiling

Genetic

Molecular and functional analysis of biospecimens, including tumor-normal Whole-exome sequencing, bulk and single-cell RNAsequencing, spatial proteomics, functional testing.

Primary outcomes

  1. Recruitment and collection of real-world clinical data from ovarian cancer patients

    Time frame: 5 years

    Prospective recruitment and collection of clinical data from 500 ovarian cancer patients. Fraction of patients from which the collection of clinical data including patient age, tumor stage, histological diagnoses have been collected.

  2. Successful collection and translational analysis of biospecimens

    Time frame: 5 years

    Fraction of the recruited patients, from which tumor, ascites, and/or peripheral blood samples that have been successfully collected and subjected to molecular profiling.

Secondary outcomes

  1. Discovery of candidate prognostic and predictive biomarkers

    Time frame: 5 years

    Number of clinical and/or molecular features which of statistically significantly correlate to patient treatment outcomes (response to chemotherapy by RECIST1.1, Progression Free survival, Overall Survival).

Study contacts

Contact information is provided by the study sponsor or research team.

Anniina Färkkilä, MD PhD

CONTACT

[email protected]

+358504272060

Sponsors and collaborators

Lead sponsor

University of Helsinki

Other

Collaborators

  • Helsinki University Central Hospital

Registry information

Acronym: ONCOSYS-OVA

Important dates

Study start
2022
Primary completion
2027
Study completion
2027
First posted
Nov 7, 2023
Registry last updated
Nov 7, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.